Inventor

BJORKMAN PAMELA J

US33 patents

⚠️ This page may combine multiple inventors who share the name “BJORKMAN PAMELA J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BJORKMAN PAMELA J

UNIV ROCKEFELLER

Broadly-neutralizing anti-HIV antibodies

Human immunodeficiency virus neutralizing antibodies and methods of use thereof

HIV-1 gp120 CD4 binding site antibodies targeting HIV escape mutants

Human immunodeficiency virus neutralizing antibodies and methods of use thereof

Human immunodeficiency virus neutralizing antibodies and methods of use thereof

Human immunodeficiency virus neutralizing antibodies and methods of use thereof

Broadly neutralizing antibodies that target HIV ENV V3 N-glycans

Broadly-neutralizing anti-HIV antibodies

Nucleic acids encoding broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 ENV subunits

Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof

Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof

Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof

HIV vaccine immunogens

Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits

CALIFORNIA INST OF TECHN

Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth

Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5

Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases

Antibodies targeting HIV escape mutants

Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases

Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with gp120

HIV-1 GP120 CD4 binding site antibodies targeting HIV escape mutants

Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases

Anti-HIV vaccine antibodies with reduced polyreactivity

Multivalent carriers and related vaccine compositions

BIO RAD LABORATORIES

Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases

Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases

Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases

The Rockefeller Universtiy

Broadly-neutralizing anti-HIV antibodies

Broadly neutralizing antibody directed against HIV-1 GP140

SCHEID JOHANNES

Human immunodeficiency virus neutralizing antibodies and methods of use thereof

DISKIN RON

Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120